Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757141 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
A Phase 1 study of Vanishing White Matter Disease, sponsored by Calico Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT05757141: Recruiting Phase 1 study of Vanishing White Matter Disease, sponsored by Calico Life Sciences.
NCT05757141 is a Phase 1 study of Vanishing White Matter Disease that is actively recruiting participants, run by Calico Life Sciences. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757141, a Phase 1 study of Vanishing White Matter Disease, is actively recruiting participants, sponsored by Calico Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
Primary Outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Conditions Studied
Interventions
- DRUG Fosigotifator
Study Locations (5)
Massachusetts
- Massachusetts General Hospital /ID# 270960 - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Utah
- University of Utah /ID# 255624 - Salt Lake City
Quebec
- McGill University Health Centre - Glen Site - Montreal
North Holland
- Amsterdam UMC, locatie VUmc /ID# 270955 - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2029-11 |
| Phase | Phase 1 |
What NCT05757141 shows while recruiting
NCT05757141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Vanishing White Matter Disease appearing as the primary indexed condition, and to 1 intervention - of which Fosigotifator is the first listed.
NCT05757141 lists 5 locations in 5 states (Massachusetts, Pennsylvania, Utah).
Frequently Asked Questions
What is clinical trial NCT05757141 about?
NCT05757141 is a clinical study titled "An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease". Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. P...
What is the current status of trial NCT05757141?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-03-13. Estimated completion is 2029-11.
What conditions does trial NCT05757141 study?
This clinical trial studies the following conditions: Vanishing White Matter Disease.
What interventions are being tested in trial NCT05757141?
The interventions under investigation include: Fosigotifator (DRUG).
Who is sponsoring clinical trial NCT05757141?
This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757141 being conducted?
This trial has 5 study locations across Massachusetts, Pennsylvania, Utah, Quebec, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vanishing White Matter Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05757141's enrollment target sits among peer trials
50 974th of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI